Patents by Inventor Arkadii Vaisburg

Arkadii Vaisburg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of cell adhesion, methods and compositions therefor
    Patent number: 10494345
    Abstract: Compounds with activity as modulators of cell adhesion are disclosed. The compounds are derivatives of piperidin-4-amine. In some embodiments, a compound can be linked to a targeting agent, a pharmaceutically active substance and/or a support material. Methods for enhancing or inhibiting classical cadherin-mediated functions are also disclosed. The compounds can be used for the treatment or prevention of a variety of diseases including cancer. Compositions and devices, including skin patches comprising a compound are also disclosed. In addition, methods of synthesis of the compounds are provided.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: December 3, 2019
    Assignee: Zonula, Inc.
    Inventors: Arkadii Vaisburg, Orest William Blaschuk
  • Modulators of cell adhesion, methods and compositions therefor
    Publication number: 20190100493
    Abstract: Compounds with activity as modulators of cell adhesion are disclosed. The compounds are derivatives of piperidin-4-amine. In some embodiments, a compound can be linked to a targeting agent, a pharmaceutically active substance and/or a support material. Methods for enhancing or inhibiting classical cadherin-mediated functions are also disclosed. The compounds can be used for the treatment or prevention of a variety of diseases including cancer. Compositions and devices, including skin patches comprising a compound are also disclosed. In addition, methods of synthesis of the compounds are provided.
    Type: Application
    Filed: October 1, 2018
    Publication date: April 4, 2019
    Inventors: Arkadii Vaisburg, Orest William Blaschuk
  • LSD1 inhibitors
    Patent number: 10233152
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 19, 2019
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, Jr.
  • LSD1 inhibitors
    Patent number: 10059668
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: August 28, 2018
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Arkadii Vaisburg, Matthew Arnold Marx
  • LSD1 Inhibitors
    Publication number: 20180127369
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: October 5, 2017
    Publication date: May 10, 2018
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, JR.
  • LSD1 inhibitors
    Patent number: 9809541
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: November 7, 2017
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, Jr.
  • LSD1 Inhibitors
    Publication number: 20170183308
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: November 3, 2016
    Publication date: June 29, 2017
    Applicant: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, JR.
  • LSD1 Inhibitors
    Publication number: 20170129857
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: November 3, 2016
    Publication date: May 11, 2017
    Applicant: Mirati Therapeutics, Inc.
    Inventors: Arkadii Vaisburg, Matthew Arnold Marx
  • Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
    Patent number: 9636298
    Abstract: The invention relates to prodrugs for use in the inhibition of histone deacetylase. The prodrugs of the present invention have good aqueous solubility and good aqueous stability. The prodrugs of the invention advantageously are metabolized to the active ingredient in plasma or in the blood stream of a warm-blooded animal. The invention also provides compositions and, and methods for making the prodrugs, and methods for using the prodrugs to treat fungal infections.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: May 2, 2017
    Inventors: Alain Ajamian, Yves Andre Chantigny, Arkadii Vaisburg, Franck Raeppel, Stephane Raeppel, Robert Deziel
  • Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs
    Publication number: 20150203517
    Abstract: The invention relates to prodrugs for use in the inhibition of histone deacetylase. The prodrugs of the present invention have good aqueous solubility and good aqueous stability. The prodrugs of the invention advantageously are metabolized to the active ingredient in plasma or in the blood stream of a warm-blooded animal. The invention also provides compositions and, and methods for making the prodrugs, and methods for using the prodrugs to treat fungal infections.
    Type: Application
    Filed: January 15, 2015
    Publication date: July 23, 2015
    Inventors: Alain Ajamian, Yves Andre Chantigny, Arkadii Vaisburg, Franck Raeppel, Stephane Raeppel, Robert Deziel
  • Processes and intermediates for preparing fused heterocyclic kinase inhibitors
    Patent number: 9018378
    Abstract: This invention relates to intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: April 28, 2015
    Assignee: Methylgene Inc.
    Inventors: Franck Raeppel, Ljubomir Isakovic, Stephen William Claridge, Michael Mannion, Lijie Zhan, Marie-Claude Granger, Arkadii Vaisburg
  • Processes and intermediates for preparing fused heterocyclic kinase inhibitors
    Patent number: 8907091
    Abstract: This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: December 9, 2014
    Assignee: Methylgene Inc.
    Inventors: Franck Raeppel, Ljubomir Isakovic, Stephen William Claridge, Michael Mannion, Lijie Zhan, Marie-Claude Granger, Arkadii Vaisburg, Miguel Nantel
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8906852
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: December 9, 2014
    Assignee: MethylGene Inc.
    Inventors: Stéphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frédéric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
  • METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
    Publication number: 20140315801
    Abstract: This invention relates to methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions using compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to the methods of treatment which utilize compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 23, 2014
    Inventors: Stéphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frederic Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8846927
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: September 30, 2014
    Assignee: MethylGene Inc.
    Inventors: Stephen William Claridge, Ljubomir Isakovic, Michael Mannion, Stephane Raeppel, Oscar Mario Saavedra, Frederic Gaudette, Lijie Zhan, Arkadii Vaisburg
  • METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY
    Publication number: 20140179632
    Abstract: This invention relates to methods for inhibiting kinase activity and/or inhibiting angiogenesis and/or treating a disease responsive to inhibition of kinase activity and/or treating a cell proliferative disease and/or treating an ophthalmic disease, condition or disorder treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions comprising administering novel compounds that inhibit protein tyrosine kinase activity.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: MethylGene Inc.
    Inventors: Michael Mannion, Stephane Raeppel, Stephen William Claridge, Frederic Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8759522
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: June 24, 2014
    Assignee: Methylgene Inc.
    Inventors: Michael Mannion, Stephane Raeppel, Stephen William Claridge, Frederic Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8729268
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: May 20, 2014
    Assignee: MethylGene Inc.
    Inventors: Michael Mannion, Stéphane Raeppel, Stephen William Claridge, Frédéric Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Inhibitors of histone deacetylase
    Patent number: 8598168
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: December 3, 2013
    Assignee: MethylGene Inc.
    Inventors: Oscar Moradei, Isabelle Paquin, Sylvie Frechette, Tammy Mallais, Simon Roy, Roger Machaalani, Arkadii Vaisburg, Jeffrey M Besterman, Pierre Tessier, David Smil, Silvana Leit, Robert Déziel
  • Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors
    Publication number: 20130310564
    Abstract: This invention relates to intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.
    Type: Application
    Filed: July 19, 2013
    Publication date: November 21, 2013
    Applicant: MethylGene Inc.
    Inventors: Franck Raeppel, Ljubomir Isakovic, Stephen William Claridge, Michael Mannion, Lijie Zhan, Marie-Claude Granger, Arkadii Vaisburg